Impaired function of circulating dendritic cells in patients with pancreatic cancer

Clinical Immunology

Volumn 114, Issue 1, 2005, Pages 52-60

  Yanagimoto, Hiroaki ^a   Takai, Soichiro ^a   Satoi, Sohei ^a   Toyokawa, Hideyoshi ^a   Takahashi, Kanji ^a   Terakawa, Naoyoshi ^a   Kwon, A Hon ^a   Kamiyama, Yasuo ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Circulating dendritic cell; Pancreatic cancer

Indexed keywords

ALLOANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CELL ACTIVITY; CELL COUNT; CELL PROLIFERATION; CELL STIMULATION; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; INTERMETHOD COMPARISON; MALE; PANCREAS CANCER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

AGED; ANTINEOPLASTIC AGENTS; CELL COUNT; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-12; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 10444276420     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2004.09.007     Document Type: Article

References (44)

1. R.M. Steinman The dendritic cell system and its role in immunogenicity Annu. Rev. Immunol. 9 1991 271 296
2. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
3. K. Inaba, J.P. Metlay, M.T. Crowley, and R.M. Steinman Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ J. Exp. Med. 172 1990 631 640
4. K.L. Rock, L. Rothstein, S. Gamble, and C. Fleischacker Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules J. Immunol. 150 1993 438 446
5. A.Y.C. Huang, P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens Science 264 1994 961 965
6. + subset of human blood dendritic cells is a direct precursor of Langerhans cells J. Immunol. 163 1999 1409 1419
7. U. O'Doherty, M. Peng, and S. Gezelter Human blood contains two subsets of dendritic cells, one immunologically mature and other immature Immunology 82 1994 487 493
8. H. Toyokawa, M. Inaba, S. Takai, S. Satoi, J. Beuth, H.L. Ko, Y. Matsui, A.H. Kwon, Y. Kamiyama, and S. Ikehara Enhancement of circulating dendritic cell activity by immunomodulators (OK432 and KP-40) Anticancer Res. 22 2002 2137 2145
9. T. Ito, R. Amakawa, M. Inaba, S. Ikehara, K. Inaba, and S. Fukuhara Differential regulation of human blood dendritic cell subsets by IFNs J. Immunol. 166 2001 2961 2969
10. S. Takai, S. Satoi, H. Toyokawa, and Y. Kamiyama Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience Pancreas 26 2003 243 249
11. R.H. Janes Jr., J.E. Niederhuber, J.S. Chmiel, D.P. Winchester, K.C. Ocwieja, J.H. Karnell, R.E. Clive, and H.R. Menck National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer Ann. Surg. 223 1996 261 272
12. J.P. Hoffman, P. O'Dwyer, H. Salazar, and N. Ahmad Preoperative chemoradiotherapy for localized pancreatic carcinoma. A perspective Cancer 78 1996 527 592
13. J.P. Hoffman, S. Lipsitz, T. Pisansky, J.L. Weese, L. Solin, and A.B. Benson III Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, respectable adenocarcinoma of the pancreas: an eastern cooperative oncology group study J. Clin. Oncol. 16 1998 317 323
14. H. Snady, H. Bruckner, A. Cooperman, J. Paradiso, and L. Kiefer Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial Cancer 89 2000 314 327
15. R. White, C. Lee, M. Anscher, M. Gottfried, R. Wolff, M. Keogan, T. Pappas, H. Hurwitz, and D. Tyler Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas Ann. Surg. Oncol. 6 1999 38 45
16. R.S. Yeung, J.L. Weese, J.P. Hoffman, L.J. Solin, A.R. Paul, P.F. Engstrom, S. Litwin, M.J. Kowalyshyn, and B.L. Eisenberg Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II study Cancer 722 1993 124 133
17. F.A. Wenger, C.A. Jacobi, J. Zieren, W. Docke, H.D. Volk, and J.M. Muller Tumor size and lymph-node status in pancreatic carcinoma-Is there a correlation to the preoperative immune function? Langenbeck's Arch. Surg. 384 1999 473 478
18. Y. Yamaguchi, I. Takashima, M. Funakoshi, H. Kawami, and T. Toge Defective natural killer activity in gastric cancer patients: possible involvement of suppressor factor receptor In Vivo 8 1994 279 283
19. K. Funa, B. Nilsson, G. Jacobsson, and G.V. Alm Decreased natural killer cell activity and interferon production by leucocytes in patients with adenocarcinoma of the pancreas Br. J. Cancer 50 1984 231 233
20. C.M. Balch, P.A. Dougherty, and A.B. Tilden Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients Ann. Surg. 196 1982 645 650
21. L.H. Sobin C.H. Wittekind TNM Classification of Malignant Tumors sixth ed. 2002 John Wiley and Sons, Inc. New York
22. B. Almand, J.R. Resser, B. Lindman, S. Nadaf, J.I. Clark, E.D. Kwon, D.P. Carbone, and D.I. Gabrilovich Clinical significance of defective dendritic cell differentiation in cancer Clin. Cancer Res. 6 2000 1755 1766
23. S. Ferrari, B. Rovati, C. Porta, P.E. Alessandrino, A. Bertolini, E. Collova, A. Riccardi, and M. Danova Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor Cancer Immunol. Immunother. 52 2003 359 366
24. P. Chaux, M. Moutet, J. Faivre, F. Martin, and M. Martin Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation Lab. Invest. 74 1996 975 983
25. D.I. Gabrilovich, I.F. Ciernik, and D.P. Carbone Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts Cell 1996 101 110
26. A.H. Enk, H. Jonuleit, J. Saloga, and J. Knop Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma Int. J. Cancer 73 1997 309 316
27. D.I. Gabrilovich, J. Corak, I.F. Ciernik, D. Kavanaugh, and D.P. Carbone Decreased antigen presentation by dendritic cells in patients with breast cancer Clin. Cancer Res. 1997 483 490
28. C.D. Heidecke, W. Heike, and F. Marcus Neoadjuvant treatment of esophageal cancer: immunosuppression following combined radiochemotherapy Surgery 132 2002 495 501
29. C. Belka, H. Ottinger, and E. Kreuzfelder Impact of localized radiotherapy on blood immune cells counts and function in humans Radiother. Oncol. 50 1999 199 204
30. D. Sulitzeanu Immunosuppressive factors in human cancer Adv. Cancer Res. 60 1993 247 267
31. Y. Yamaguchi, H. Tumura, M. Miwa, and K. Inaba Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow Stem Cells 15 1997 144
32. Y. Zhang, Y.Y. Zhang, M. Ogata, P. Chen, A. Harada, S. Hashimoto, and K. Matsushima Transforming growth factor-β1 polarizes murine hematopoietic progenitor cells to generate Langerhans cell-like dendritic cells through a monocyte/macrophage differentiation pathway Blood 93 1999 1208
33. C.A. Bonham, L. Lu, R.A. Banas, P. Fontes, A.S. Rao, T.E. Starzl, A. Zeevi, and A.W. Thomson TGF-beta 1 pretreatment impairs the allostimulatory function of human bone marrow-derived antigen-presenting cells for both naïve and primed T cells Transplant Immunol. 4 1996 186
34. G. Holland, and A. Zlotnik Interleukin-10 and cancer Cancer Invest. 11 1993 751 758
35. C. Botti, E. Seregni, and L. Ferrani Immunosuppressive factors: role in cancer development and progression Int. J. Biol. Markers 13 1998 51 69
36. J. Massague, S. Cheifetz, and M. Laiho Transforming growth factor-β Cancer Surv. 12 1992 81 103
37. H. Wunderlich, T. Steiner, and H. Kosmehl Increased transforming growth factor β1 plasma level in patients with renal cell carcinoma: a tumor-specific marker? Urol. Int. 60 1998 205 207
38. V. Ivanovic, A. Melman, and B. Davis-Joseph Elevated levels of TGF-β1 in patients with invasive prostate cancer Nat. Med. 1 1995 282 284
39. Y. Shirai, S. Kawata, and N. Ito Elevated levels of transforming growth factor-β in patients with hepatocellular carcinoma Jpn. J. Cancer Res. 83 1992 676 679
40. K. Shim, K. Kim, and B. Park Increased serum levels of transforming growth factor-á in patients with colorectal cancer Dis. Colon Rectum 41 1998 219 224
41. W. von Bernstorff, M. Voss, S. Freichel, A. Schmid, I. Vogel, C. Johnk, D. Henne-Bruns, B. Kremer, and H. Kalthoff Systemic and local immunosuppression in pancreatic cancer patients Clin. Cancer Res. 7 2001 925s 932s
42. M. Nakamura, M. Katano, and A. Kuwahara Transforming growth factor β1 (TGF-β1) is a preoperative prognostic indicator in advanced gastric carcinoma Br. J. Cancer 78 1998 1373 1478
43. J. Xu, J. Menezes, and U. Prasad Elevated serum levels of transforming growth factor β1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients Int. J. Cancer 84 1999 396 399
44. J.J. Kobie, R.S. Wu, R.A. Kurt, S. Lou, M.K. Adelman, L.J. Whitesell, L.V. Ramanathapuram, C.L. Arteaga, and E.T. Akporiaye Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines Cancer Res. 63 2003 1860 1864